Recombinant Proteins Market by Product (Growth Factors, Chemokines, Membrane Proteins, Receptors), Host Cell (Mammalian, Insect, Yeast), Application (Drug Discovery, Development [Biologics, CGT, Vaccines], Research, Production)- Global Forecast to 2031

Market Size
$2.63B
MARKET SIZE, 2026
Projected Market Size
$3.90B
MARKET SIZE, 2031
CAGR
8.2%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

RECOMBINANT PROTEINS MARKET SIZE, SHARE & GROWTH SNAPSHOT

recombinant-proteins-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global recombinant proteins market is projected to grow from USD 2.63 billion in 2026 to USD 3.90 billion by 2031, at a CAGR of 8.2% during the forecast period. The market was valued at USD 2.47 billion in 2025. Market growth is driven by the expanding pipeline of recombinant therapeutics, increasing demand for biologics, and growing applications in drug discovery, vaccine development, diagnostics, and cell and gene therapy. Advances in protein engineering, mammalian expression systems, and purification technologies are improving protein yield, stability, biological activity, and manufacturing scalability. Increasing use of recombinant growth factors, chemokines, enzymes, receptors, and immune-related proteins across pharmaceutical, biotechnology, and research settings is accelerating market adoption. Additionally, rising investments in biopharmaceutical manufacturing and growing demand for high-purity, consistent, and application-specific recombinant proteins are supporting market expansion.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2025): USD 2.47 Billion
    Current Market Size (2026): USD 2.63 Billion
    Forecast Market Size (2031): USD 3.90 Billion
    CAGR (2026–2031): 8.2%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America accounted for the largest share of 46.3% of the recombinant proteins market in 2025.
    Product Leader: Growth factors & chemokines accounted for the largest share of 34.9% in 2025.
    Expression System Leader: Bacterial cells accounted for the largest share of 38.1% in 2025.
    Application Leader: Drug discovery & development accounted for the largest share of 37.2% in 2025.
    End User Leader: Pharmaceutical & biopharmaceutical companies accounted for the largest share of 46.3% in 2025.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Bio-Techne (US) were identified as some of the star players in the recombinant proteins market, given their strong market share and product footprint.
    Companies such as RayBiotech, Inc. (US), Icosagen (South Korea), and Qkine Ltd. (China), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The recombinant proteins market is growing due to the expanding pipeline of recombinant therapeutics, increasing demand for biologics, and wider applications in drug discovery, vaccine development, diagnostics, and cell and gene therapy. Advances in protein engineering, expression systems, and purification technologies are improving protein yield, stability, and biological activity, supporting adoption across research and biopharmaceutical manufacturing.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The recombinant proteins market is evolving through advances in protein engineering, expression systems, and purification technologies that improve protein yield, stability, biological activity, and consistency. Increasing adoption of engineered recombinant proteins, including growth factors, chemokines, enzymes, receptors, and immune-related proteins, is supporting applications across drug discovery, biologics development, vaccine production, diagnostics, and cell and gene therapy. Advances in mammalian expression systems, optimized cell-line development, and scalable bioprocessing are enabling more efficient production of complex therapeutic proteins. Additionally, growing demand for high-purity, application-specific proteins and ready-to-use formulations is supporting broader adoption across pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations. These developments are strengthening protein production capabilities, supporting biopharmaceutical manufacturing, and creating opportunities for the development of novel recombinant therapeutics.

recombinant-proteins-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing pipeline for recombinant therapeutic proteins
  • Shift toward mammalian expression systems
RESTRAINTS
Impact
Level
  • High lot-to-lot variability and inconsistency in off-the-shelf recombinant proteins
  • High costs associated with premium recombinant proteins expressed in mammalian cells
OPPORTUNITIES
Impact
Level
  • Emergence of ready-to-use liquid formulations for integration into automated high-throughput workflows
  • Development of bio-engineered, heat-stable protein variants for continuous cell lines & cell culture
CHALLENGES
Impact
Level
  • Advent of non-protein mimics and alternative modalities
  • Rising supply chain complexities

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing pipeline for recombinant therapeutic proteins

The expanding pipeline of recombinant therapeutics is driving demand across drug discovery and clinical development. Increasing development of proteins for cancer, autoimmune disorders, and genetic diseases is supporting their use in target validation, functional assays, and therapeutic development. Advances in protein engineering and expression technologies are further enabling the development of complex biologics and engineered proteins.

Restraint: High lot-to-lot variability and inconsistency in off-the-shelf recombinant proteins

Variability in protein purity, biological activity, folding, and post-translational modifications can affect experimental reproducibility and biopharmaceutical workflows. Differences between batches and expression systems may influence protein performance in drug discovery, cell culture, and functional assays, increasing validation requirements, development costs, and research timelines.

Opportunity: Emergence of ready-to-use liquid formulations for integration into automated high-throughput workflows

Ready-to-use liquid recombinant proteins can improve workflow efficiency, reduce preparation time, and support automated high-throughput screening. Standardized formulations simplify handling and minimize preparation-related variability. Growing automation in drug discovery, biologics development, and cell culture creates opportunities for suppliers offering stable, application-specific proteins in convenient formats.

Challenge: Advent of non-protein mimics and alternative modalities

Recombinant proteins face competition from alternative modalities, including small molecules, peptides, and nucleic acid-based therapies. Depending on the application, these alternatives may offer advantages in delivery, stability, manufacturing, or cost. Recombinant protein developers must demonstrate strong biological activity, safety, efficacy, and commercial value to remain competitive.

RECOMBINANT PROTEINS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Recombinant cytokines and growth factors from its Gibco, Invitrogen, and PeproTech brands are used in cell culture, drug discovery, immunology research, stem cell expansion, and cell therapy manufacturing. Its GMP-grade proteins support the production of cell-based therapies. Supports reproducible cell culture and immune-cell expansion | Enables research-to-manufacturing workflows | Supports clinical manufacturing requirements through GMP-grade proteins.
company logo
Merck provides recombinant protein expression and process-development technologies for biopharmaceutical applications. Its CHOZN expression platform and associated process-development services support the development and scale-up of recombinant proteins and other biologics. Supports high-producing cell-line development | Facilitates process optimization and scale-up | Helps improve manufacturing productivity and consistency.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The recombinant proteins market ecosystem comprises raw material providers, technology and equipment manufacturers, service providers, end users, and regulatory authorities. Raw material suppliers, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Danaher Corporation (US), provide culture media, expression reagents, and purification materials. Product providers, including Thermo Fisher Scientific Inc. (US), Bio-Techne (US), GenScript (China), Sino Biological, Inc. (China), and Abnova Corporation (Taiwan), supply recombinant proteins and custom expression services for drug discovery, biologics development, and research. End users, including pharmaceutical and biopharmaceutical companies, biotechnology companies, CROs, and academic and research institutes, use recombinant proteins in therapeutic development, vaccine research, diagnostics, and biotechnology research. Regulatory authorities, including the US FDA, EMA, and CDSCO, establish quality, safety, and manufacturing requirements, particularly for recombinant proteins intended for therapeutic applications.

recombinant-proteins-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

recombinant-proteins-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Recombinant Proteins Market, By Product

In 2025, the growth factors & chemokines segment dominated the recombinant proteins market, driven by their extensive use in cell culture, cell signaling, drug discovery, and therapeutic development. Increasing demand for cytokines, chemokines, and growth factors in stem cell research, cancer studies, and biologics development supports segment growth. Advances in protein engineering and the growing need for high-purity, application-specific proteins further strengthen demand.

Recombinant Proteins Market, By Host Cell

In 2025, the bacterial cells segment dominated the recombinant proteins market, owing to their rapid growth, cost-effective cultivation, and ease of genetic manipulation. These systems, particularly E. coli, are widely used to produce recombinant proteins for research, enzyme production, and selected therapeutic applications. Established production processes, scalability, and lower manufacturing costs compared with mammalian expression systems further support the adoption of bacterial cells.

Recombinant Proteins Market, By Application

In 2025, the drug discovery & development segment dominated the recombinant proteins market, supported by the growing use of recombinant proteins in target validation, functional assays, disease modeling, and drug screening. Pharmaceutical and biotechnology companies increasingly use these proteins to investigate biological pathways and assess potential drug candidates. Growing biologics pipelines and demand for reliable, high-quality research reagents further support adoption in drug discovery and development.

RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX

In the recombinant proteins market company evaluation matrix, Thermo Fisher Scientific Inc. (US) is positioned as a star player due to its broad portfolio of recombinant proteins, including growth factors, cytokines, chemokines, and other proteins offered through its Gibco, Invitrogen, and PeproTech brands. Its extensive product range, global distribution network, and support for drug discovery, cell culture, and biopharmaceutical development strengthen its competitive position. Sino Biological, Inc. (China) is considered an emerging leader in the recombinant proteins market. The company offers an extensive portfolio of recombinant proteins, including cytokines, growth factors, enzymes, and membrane proteins, alongside custom protein expression and production services. Its specialized protein expertise, expanding product portfolio, and support for drug discovery, antibody development, and biomedical research strengthen its position in the market.

recombinant-proteins-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2026 (Value) USD 2.63 Billion
Market Forecast in 2031 (Value) USD 3.90 Billion
Growth Rate CAGR of 8.2% from 2026-2031
Years Considered 2023-2031
Base Year 2025
Forecast Period 2026-2031
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Product:
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Structural Proteins
    • Membrane Proteins
    • Kinase Proteins
    • Regulatory Proteins
    • Recombinant Metabolic Enzymes
    • Adhesion Molecules & Receptors
    • Other Recombinant Proteins
  • By Host Cell:
    • Mammalian Cells
    • Insect Cells
    • Yeast & Fungi
    • Bacterial Cells
    • Other Host Cells
  • By Application:
    • Drug Discovery & Development
    • Research
    • Biopharmaceutical Production
    • Diagnostics
    • Other Applications
  • By End User:
    • Pharmaceutical & Biopharmaceutical Companies
    • Biotechnology Companies
    • Academic & Research Institutes
    • Contract Research Organizations (CROs)
    • Other End Users
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa

WHAT IS IN IT FOR YOU: RECOMBINANT PROTEINS MARKET REPORT CONTENT GUIDE

recombinant-proteins-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Rest of Europe Breakdown Country-level market sizing and growth forecasts (Switzerland, Sweden, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia) Provides granular country-level insights, enabling clients to prioritize high-growth markets
Company Evaluation
  • Detailed analysis and profiling of top five market players
  • Portfolio assessment of top five companies
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions

RECENT DEVELOPMENTS

  • July 2026 : Merck opened a BioReliance testing facility in Darmstadt, Germany, to enhance access to drug substance and product release testing in Europe. The site supports biologics developers, including recombinant protein manufacturers, by providing GMP-compliant analytical and biosafety testing services closer to production.
  • April 2026 : Miltenyi Biotec launched a research-grade recombinant human IL-18, a pro-inflammatory cytokine optimized for in vitro and in vivo studies. This product is designed for researchers focused on immune modulation, inflammation, and cell-based therapies, enhancing Miltenyi’s recombinant protein portfolio for research applications.
  • September 2025 : Integrated DNA Technologies, a Danaher company, launched a research-grade recombinant enhancer protein aimed at improving the efficiency of CRISPR homology-directed repair. This protein enhances the CRISPR nuclease toolkit, facilitating the development of gene-editing workflows that utilize recombinant proteins for translational and clinical research.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
15
2
EXECUTIVE SUMMARY
 
 
 
 
 
3
PREMIUM INSIGHTS
 
 
 
 
 
4
MARKET OVERVIEW
Captures industry movement, adoption patterns, and strategic signals across key end-use segments and regions.
 
 
 
 
 
 
4.1
INTRODUCTION
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
4.2.1.1
GROWING PIPELINE FOR RECOMBINANT THERAPEUTIC PROTEINS
 
 
 
 
 
4.2.1.2
SHIFT TOWARD MAMMALIAN EXPRESSION SYSTEMS
 
 
 
 
 
4.2.1.3
INCREASING DEMAND FOR ENGINEERED RECOMBINANT PROTEINS
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
4.2.2.1
HIGH LOT-TO-LOT VARIABILITY AND INCONSISTENCY IN OFF-THE-SHELF RECOMBINANT PROTEINS
 
 
 
 
 
4.2.2.2
HIGH COSTS ASSOCIATED WITH PREMIUM RECOMBINANT PROTEINS EXPRESSED IN MAMMALIAN CELLS
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
4.2.3.1
EMERGENCE OF READY-TO-USE LIQUID FORMULATIONS FOR INTEGRATION INTO AUTOMATED HIGH-THROUGHPUT WORKFLOWS
 
 
 
 
 
4.2.3.2
DEVELOPMENT OF BIO-ENGINEERED, HEAT-STABLE PROTEIN VARIANTS FOR CONTINUOUS CELL LINES & CELL CULTURE
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
4.2.4.1
ADVENT OF NON-PROTEIN MIMICS AND ALTERNATIVE MODALITIES
 
 
 
 
 
4.2.4.2
RISING SUPPLY CHAIN COMPLEXITIES
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
5
INDUSTRY TRENDS
Presents a concise view of industry direction, strategic priorities, and key indicators influencing market momentum.
 
 
 
 
 
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
5.1.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
5.1.2
THREAT OF SUBSTITUTES
 
 
 
 
 
5.1.3
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
5.1.4
BARGAINING POWER OF BUYERS
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITION RIVALRY
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
 
 
 
 
 
5.2.4
TRENDS IN GLOBAL BIOTECH INDUSTRY
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
5.5.1
AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023-2025
 
 
 
 
 
5.5.2
AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025
 
 
 
 
5.6
TRADE ANALYSIS (2021-2025)
 
 
 
 
 
 
 
5.6.1
EXPORT SCENARIO (HS CODE 3822.00)
 
 
 
 
 
5.6.2
IMPORT SCENARIO (HS CODE 3822.00)
 
 
 
 
5.7
KEY CONFERENCES & EVENTS, 2026-2027
 
 
 
 
 
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
 
 
 
 
 
5.9
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
5.10
CASE STUDY ANALYSIS
 
 
 
 
 
5.11
IMPACT OF 2025 US TARIFF – RECOMBINANT PROTEINS MARKET
 
 
 
 
 
 
 
5.11.1
INTRODUCTION
 
 
 
 
 
5.11.2
KEY TARIFF RATES
 
 
 
 
 
5.11.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
5.11.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
5.11.4.1
US
 
 
 
 
 
5.11.4.2
EUROPE
 
 
 
 
 
5.11.4.3
APAC
 
 
 
 
5.11.5
IMPACT ON END USE INDUSTRIES
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
 
 
 
 
 
 
6.1
KEY TECHNOLOGIES
 
 
 
 
 
 
6.1.1
CODON OPTIMIZATION
 
 
 
 
 
6.1.2
CRISPR/CAS9 ENGINEERING
 
 
 
 
 
6.1.3
TRANSIENT GENE EXPRESSION (TGE)
 
 
 
 
6.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
6.2.1
AFFINITY CHROMATOGRAPHY
 
 
 
 
 
6.2.2
TANGENTIAL FLOW FILTRATION (TFF) & ULTRAFILTRATION
 
 
 
 
6.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
6.3.1
GENE EDITING
 
 
 
 
 
6.3.2
SPATIAL MULTI-OMICS
 
 
 
 
6.4
TECHNOLOGY ROADMAP
 
 
 
 
 
6.5
PATENT ANALYSIS
 
 
 
 
 
 
6.6
FUTURE APPLICATIONS
 
 
 
 
 
6.7
IMPACT OF AI/ GEN AI ON RECOMBINANT PROTEINS MARKET
 
 
 
 
 
 
 
6.7.1
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
 
6.7.2
BEST PRACTICES IN AI-ENABLED RECOMBINANT PROTEIN DISCOVERY, DESIGN, AND WORKFLOWS
 
 
 
 
 
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN RECOMBINANT PROTEINS MARKET
 
 
 
 
 
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
 
 
 
 
 
6.7.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED RECOMBINANT PROTEINS SOLUTIONS
 
 
 
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
 
 
 
 
 
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
 
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
 
 
 
 
 
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
 
 
 
 
 
 
8.1
INTRODUCTION
 
 
 
 
 
8.2
DECISION-MAKING PROCESS
 
 
 
 
 
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
 
 
 
 
 
 
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
8.3.2
BUYING CRITERIA
 
 
 
 
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
9
RECOMBINANT PROTEINS MARKET, BY PRODUCT, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
 
COMPARATIVE ASSESSMENT OF KEY PRODUCTS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
 
 
 
 
 
 
9.1
INTRODUCTION
 
 
 
 
 
9.2
GROWTH FACTORS & CHEMOKINES
 
 
 
 
 
 
9.2.1
INTERFERONS
 
 
 
 
 
9.2.2
INTERLEUKINS
 
 
 
 
 
9.2.3
OTHER GROWTH FACTORS & CHEMOKINES
 
 
 
 
9.3
IMMUNE RESPONSE PROTEINS
 
 
 
 
 
9.4
STRUCTURAL PROTEINS
 
 
 
 
 
9.5
MEMBRANE PROTEINS
 
 
 
 
 
9.6
KINASE PROTEINS
 
 
 
 
 
9.7
REGULATORY PROTEINS
 
 
 
 
 
9.8
RECOMBINANT METABOLIC ENZYMES
 
 
 
 
 
9.9
ADHESION MOLECULES & RECEPTORS
 
 
 
 
 
9.10
OTHER RECOMBINANT PROTEINS (OTHER RECOMBINANT PROTEINS INCLUDE VIRAL ANTIGENS AND OTHER PROTEINS)
 
 
 
 
10
RECOMBINANT PROTEINS MARKET, BY HOST CELL, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
 
COMPARATIVE ASSESSMENT OF HOST CELLS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
 
 
 
 
 
 
10.1
INTRODUCTION
 
 
 
 
 
10.2
MAMMALIAN CELLS
 
 
 
 
 
10.3
INSECT CELLS
 
 
 
 
 
10.4
YEAST & FUNGI CELLS
 
 
 
 
 
10.5
BACTERIAL CELLS
 
 
 
 
 
10.6
OTHER HOST CELLS (OTHER HOST CELLS INCLUDE WHEAT GERM EXTRACT SYSTEMS, MOSS CELL MAMMALIAN HYBRID SYSTEMS, AND MICROALGAE & PLANT-BASED EXPRESSION SYSTEMS)
 
 
 
 
11
RECOMBINANT PROTEINS MARKET, BY APPLICATION (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
 
COMPARATIVE ASSESSMENT OF KEY APPLICATIONS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
 
 
 
 
 
 
11.1
INTRODUCTION
 
 
 
 
 
11.2
DRUG DISCOVERY & DEVELOPMENT
 
 
 
 
 
 
11.2.1
BIOLOGICS
 
 
 
 
 
11.2.2
VACCINES
 
 
 
 
 
11.2.3
CELL & GENE THERAPY
 
 
 
 
11.3
RESEARCH
 
 
 
 
 
 
11.3.1
ACADEMIC RESEARCH
 
 
 
 
 
11.3.2
BIOTECHNOLOGY RESEARCH
 
 
 
 
11.4
BIOPHARMACEUTICAL PRODUCTION
 
 
 
 
 
11.5
DIAGNOSTICS
 
 
 
 
 
11.7
OTHER APPLICATIONS (OTHER APPLICATIONS INCLUDES RECOMBINANT PROTEIN USAGE ACROSS FORENSICS AND COSMETOLOGY)
 
 
 
 
12
RECOMBINANT PROTEINS MARKET, BY END USER (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
 
COMPARATIVE ASSESSMENT OF DEMAND PATTERNS, THEIR MARKET POTENTIAL ACROSS CUSTOMERS
 
 
 
 
 
 
12.1
INTRODUCTION
 
 
 
 
 
12.2
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
 
 
 
 
 
12.3
BIOTECHNOLOGY COMPANIES
 
 
 
 
 
12.4
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
12.5
CONTRACT RESEARCH ORGANIZATIONS (CROS)
 
 
 
 
 
12.6
OTHER END USERS (OTHER END USERS INCLUDE DIAGNOSTIC CENTERS, LABORATORIES [HOSPITAL-ATTACHED LABORATORIES (HALS), INDEPENDENT DIAGNOSTIC LABORATORIES, AND FORENSIC LABORATORIES], AND THE COSMETIC INDUSTRY)
 
 
 
 
13
RECOMBINANT PROTEINS MARKET, BY REGION, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
 
 
 
 
 
 
ASSESSMENT OF GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY GEOGRAPHIES AND COUNTRIES
 
 
 
 
 
 
13.1
INTRODUCTION
 
 
 
 
 
13.2
NORTH AMERICA
 
 
 
 
 
 
13.2.1
US
 
 
 
 
 
13.2.2
CANADA
 
 
 
 
13.3
EUROPE
 
 
 
 
 
 
13.3.1
GERMANY
 
 
 
 
 
13.3.2
UK
 
 
 
 
 
13.3.3
FRANCE
 
 
 
 
 
13.3.4
ITALY
 
 
 
 
 
13.3.5
SPAIN
 
 
 
 
 
13.3.6
REST OF EUROPE
 
 
 
 
13.4
ASIA PACIFIC
 
 
 
 
 
 
13.4.1
CHINA
 
 
 
 
 
13.4.2
JAPAN
 
 
 
 
 
13.4.3
INDIA
 
 
 
 
 
13.4.4
SOUTH KOREA
 
 
 
 
 
13.4.5
REST OF APAC
 
 
 
 
13.5
LATIN AMERICA
 
 
 
 
 
 
13.5.1
BRAZIL
 
 
 
 
 
13.5.3
REST OF LATIN AMERICA
 
 
 
 
13.6
MIDDLE EAST
 
 
 
 
 
 
13.6.1
GCC
 
 
 
 
 
13.6.2
REST OF MIDDLE EAST
 
 
 
 
13.7
AFRICA
 
 
 
 
14
COMPETITIVE LANDSCAPE
 
 
 
 
 
 
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
 
 
 
 
 
 
 
14.1
INTRODUCTION
 
 
 
 
 
14.2
KEY PLAYERS’ STRATEGIES/RIGHT TO WIN (JANUARY 2023 – SEPTEMBER 2026)
 
 
 
 
 
14.3
REVENUE ANALYSIS, 2021-2025
 
 
 
 
 
 
14.4
MARKET SHARE ANALYSIS,
 
 
 
 
 
 
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
 
 
 
 
 
 
 
14.5.1
STARS
 
 
 
 
 
14.5.2
EMERGING LEADERS
 
 
 
 
 
14.5.3
PERVASIVE PLAYERS
 
 
 
 
 
14.5.4
PARTICIPANTS
 
 
 
 
 
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
 
 
 
 
 
 
14.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
14.5.5.2
REGION FOOTPRINT
 
 
 
 
 
14.5.5.3
PRODUCT FOOTPRINT
 
 
 
 
 
14.5.5.4
APPLICATION FOOTPRINT
 
 
 
 
 
14.5.5.5
HOST CELL FOOTPRINT
 
 
 
14.6
COMPANY EVALUATION MATRIX: START-UPS/SMES,
 
 
 
 
 
 
 
14.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
14.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
14.6.3
DYNAMIC COMPANIES
 
 
 
 
 
14.6.4
STARTING BLOCKS
 
 
 
 
 
14.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
 
 
 
 
 
 
14.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
 
 
 
 
 
14.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
 
 
 
14.7
COMPETITIVE SCENARIO
 
 
 
 
 
 
14.7.1
PRODUCT LAUNCHES
 
 
 
 
 
14.7.2
DEALS
 
 
 
 
 
14.7.3
EXPANSIONS
 
 
 
 
14.8
BRAND COMPARISON
 
 
 
 
 
 
14.9
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
15
COMPANY PROFILES*
 
 
 
 
 
 
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE RECOMBINANT PROTEINS MARKET LANDSCAPE
 
 
 
 
 
 
15.1
KEY PLAYERS
 
 
 
 
 
 
15.1.1
BIO-TECHNE
 
 
 
 
 
 
15.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.1.3
MNM VIEW
 
 
 
 
 
 
15.1.1.3.1
KEY STRENGTHS/RIGHT TO WIN
 
 
 
 
 
15.1.1.3.2
STRATEGIC CHOICES
 
 
 
 
 
15.1.1.3.3
WEAKNESSES/COMPETITIVE THREATS
 
 
 
15.1.2
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
15.1.2.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.2.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.2.3
MNM VIEW
 
 
 
 
 
 
15.1.2.3.1
KEY STRENGTHS/RIGHT TO WIN
 
 
 
 
 
15.1.2.3.2
STRATEGIC CHOICES
 
 
 
 
 
15.1.2.3.3
WEAKNESSES/COMPETITIVE THREATS
 
 
 
15.1.3
MERCK KGAA
 
 
 
 
 
 
15.1.3.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.3.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.3.3
MNM VIEW
 
 
 
 
 
 
15.1.3.3.1
KEY STRENGTHS/RIGHT TO WIN
 
 
 
 
 
15.1.3.3.2
STRATEGIC CHOICES
 
 
 
 
 
15.1.3.3.3
WEAKNESSES/COMPETITIVE THREATS
 
 
 
15.1.4
DANAHER CORPORATION
 
 
 
 
 
 
15.1.4.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.4.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.4.3
MNM VIEW
 
 
 
 
 
 
15.1.4.3.1
KEY STRENGTHS/RIGHT TO WIN
 
 
 
 
 
15.1.4.3.2
STRATEGIC CHOICES
 
 
 
 
 
15.1.4.3.3
WEAKNESSES/COMPETITIVE THREATS
 
 
 
15.1.5
ABNOVA CORPORATION
 
 
 
 
 
 
15.1.5.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.5.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.5.3
MNM VIEW
 
 
 
 
 
 
15.1.5.3.1
KEY STRENGTHS/RIGHT TO WIN
 
 
 
 
 
15.1.5.3.2
STRATEGIC CHOICES
 
 
 
 
 
15.1.5.3.3
WEAKNESSES/COMPETITIVE THREATS
 
 
 
15.1.6
BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
15.1.6.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.6.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.6.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.7
BPS BIOSCIENCE, INC.
 
 
 
 
 
 
15.1.7.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.7.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.7.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.8
SINO BIOLOGICAL, INC.
 
 
 
 
 
 
15.1.8.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.8.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.8.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.9
GENSCRIPT
 
 
 
 
 
 
15.1.9.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.9.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.9.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.10
PROTEINTECH GROUP, INC.
 
 
 
 
 
 
15.1.10.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.10.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.10.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.11
MILTENYI BIOTEC
 
 
 
 
 
 
15.1.11.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.11.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.11.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.12
ENZO BIOCHEM INC.
 
 
 
 
 
 
15.1.12.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.12.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.12.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.13
REVVITY
 
 
 
 
 
 
15.1.13.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.13.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.13.3
RECENT DEVELOPMENTS
 
 
 
 
15.1.14
SARTORIUS AG
 
 
 
 
 
 
15.1.14.1
BUSINESS OVERVIEW
 
 
 
 
 
15.1.14.2
PRODUCTS OFFERED
 
 
 
 
 
15.1.14.3
RECENT DEVELOPMENTS
 
 
 
15.2
OTHER PLAYERS
 
 
 
 
 
 
15.2.1
STEMCELL TECHNOLOGIES
 
 
 
 
 
15.2.2
RAYBIOTECH, INC.
 
 
 
 
 
15.2.3
ACROBIOSYSTEMS
 
 
 
 
 
15.2.4
ICOSAGEN
 
 
 
 
 
15.2.5
PROSPEC-TANY TECHNOGENE LTD.
 
 
 
 
 
15.2.6
PROTEOGENIX
 
 
 
 
 
15.2.7
AVIVA SYSTEMS BIOLOGY CORPORATION
 
 
 
 
 
15.2.8
LAURUS BIO
 
 
 
 
 
15.2.9
UNITED STATES BIOLOGICAL
 
 
 
 
 
15.2.10
QKINE LTD.
 
 
 
 
 
15.2.11
STRESSMARQ BIOSCIENCES INC.
 
 
 
 
*THIS SECTION WILL INCLUDE A TOTAL OF ~25-30 COMPANY PROFILES. THE LIST OF COMPANIES MENTIONED ABOVE IS SUBJECT TO CHANGE AS THE STUDY PROGRESSES.
 
 
 
 
 
16
RESEARCH METHODOLOGY
 
 
 
 
 
 
16.1
RESEARCH DATA
 
 
 
 
 
 
16.1.1
SECONDARY DATA
 
 
 
 
 
 
16.1.1.1
KEY SOURCES OF SECONDARY DATA
 
 
 
 
 
16.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
 
 
 
 
16.1.2
PRIMARY DATA
 
 
 
 
 
 
16.1.2.1
BREAKDOWN OF PRIMARIES
 
 
 
 
 
16.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
 
 
 
16.2
MARKET SIZE ESTIMATION
 
 
 
 
 
 
16.2.1
GLOBAL RECOMBINANT PROTEINS MARKET SIZE ESTIMATION,
 
 
 
 
 
 
16.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
 
 
 
 
 
16.2.1.2
MNM REPOSITORY ANALYSIS
 
 
 
 
 
16.2.1.3
SECONDARY ANALYSIS
 
 
 
 
 
16.2.1.4
PRIMARY RESEARCH
 
 
 
 
 
 
16.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
 
 
 
16.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
 
 
 
 
16.3
MARKET GROWTH RATE PROJECTIONS
 
 
 
 
 
16.4
DATA TRIANGULATION
 
 
 
 
 
16.5
FACTOR ANALYSIS
 
 
 
 
 
16.6
RESEARCH LIMITATIONS & RISK ASSESSMENT
 
 
 
 
 
16.7
RISK ANALYSIS
 
 
 
 
17
APPENDIX
 
 
 
 
 
 
17.1
DISCUSSION GUIDE
 
 
 
 
 
17.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
17.3
AVAILABLE CUSTOMIZATIONS
 
 
 
 
 
17.4
RELATED REPORTS
 
 
 
 
 
17.5
AUTHOR DETAILS
 
 
 
 

Methodology

This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global recombinant proteins market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources,such as the World Health Organization, The Antibody Society,Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC),National Center for Biotechnology Information (NCBI), American Medical Association (AMA), RecombinantAntibody Network (RAN), National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), and the Institute for Molecular Medicine, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

Recombinant Protein Market 
 Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The top-down and bottom-up approaches were used to estimate & validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various market segments.

Recombinant Protein Market Top Down and Bottom Up Approach

Data Triangulation

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.

Market Definition

Recombinant proteins are manipulated proteins generated by recombinant DNA technology that modifies gene sequences. These are formed by transfecting foreign genes into a host cell. Recombinant proteins are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses. This market includes recombinant protein products, including growth factors, cytokines, recombinant enzymes, structural proteins, and membrane proteins.

Key Stakeholders

  • Pharmaceutical & Biopharmaceutical Companies
  • Biotechnology Companies
  • Life Sciences Companies
  • Academic Research Institutes
  • Government Institutes
  • Private Research Firms
  • Contract Research Organizations (CROs)
  • Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
  • Venture Capitalists and Investors
  • Market Research and Consulting Firms

Report Objectives

  • To define, describe, and forecast the recombinant proteins market based on product, host cell, application, and end user
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall recombinant proteins market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders  
  • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically profile the key players in the recombinant proteins market and comprehensively analyze their core competencies and market rankings
  • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the recombinant proteins market
  • To benchmark players within the recombinant proteins market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

Available customizations:

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the Rest of Europe recombinant proteins market, by country
  • Further breakdown of the Rest of Asia Pacific recombinant proteins market, by country
  • Further breakdown of the Rest of Latin America recombinant proteins market, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Recombinant Proteins Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Recombinant Proteins Market

avtar

Kahlill

May, 2022

What are the growth estimates for Recombinant protein market till 2026?.

avtar

James

May, 2022

What are the key factors hampering growth of the Recombinant protein market?.

avtar

Peggy

May, 2022

Interested in data of Recombinant Protein Market, Industry Share, Size, Growth and forecasts of 2027 - 2030.

avtar

John

Dec, 2022

How big is the recombinant proteins market?.

DMCA.com Protection Status
popup img